| abstract |
The present invention discloses compounds of the formula (I): wherein R1 signifies pyridyl, pyrimidinyl, isoxazolyl or thienyl which is unsubstituted or substituted by C1-6-alkyl, halogen, amino, mono- or di-C1-6-alkylamino or C1-6-alkanoyl; R2 signifies hydrogen, C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkoxy-phenyl, C1-6-alkylene-dioxyphenyl, C1-6-alkoxy-phenyl-C1-6alkyl, pyrimidinyl, pyridyl, morpholino or benzodioxolyl; R3 signifies C1-6-alkyl, C1-6-alkoxy, formyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl or a -CH2O-A-C1-6-alkyl, -(CH2)m -O-(CRaRb)Noh, -(CH2)m-O-(CRaRb)Nor9, -(CH2)m-O-(CRaRb)Nnh2 or -(CH2)m-O-(CRaRb)n-B-R9; R4-R8 signify hydrogen, C1-6-alkoxy or halogen; R9 signifies pyridyl or furyl; Ra and Rb signify hydrogen or C1-6-alkyl; A signifies a ketalized 1,2-dihydroxy-ethylene group; B signifies -OC(O)O-, -O(C(O)NH- or -NHC(O)NH-; n signifies 2, 3, or 4; and m signifies 0 or 1. Also disclosed are pharmaceutical compositions comprising the same, processes for preparing the same, and their uses. The present invention is concerned with novel sulphonamides and their use as medicaments. In particular, the invention is concerned with novel compounds of the formula, wherein R1 signifies pyridyl, pyrimidinyl, isoxazolyl or thienyl which is unsubstituted or substituted by C1-6-alkyl, halogen, amino, mono- or di-C1-6-alkylamino or C1-6-alkanoyl; R2 signifies hydrogen, C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, C1-6-alkoxy-phenyl, C1-6-alkylene-dioxyphenyl, C1-6-alkoxy-phenyl-C1-6-alkyl, pyrimidinyl, pyridyl, morpholino or benzodioxolyl; R3 signifies C1-6-alkyl, C1-6-alkoxy, formyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl or a -CH2O-A-C1-6-alkyl, -(CH2)m-O-(CR3Rb)nOH, -(CH2)m-O-(CR3Rb)nOR9, -(CH2)m-O-(CRaRb)nNH2 OR -(CH2)m-O-(CRaRb)n-B-R9; R4-R8 signify hydrogen, C1-6-alkoxy or halogen; R9 signifies pyridyl or furyl; Ra and Rb signify hydrogen or C1-6-alkyl. |